Edwards Lifesciences Total Liabilities & Equity decreased by 2.7% to $13.32B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.3%, from $13.02B to $13.32B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows an upward trend with a 13.6% CAGR.
An increase typically reflects overall balance sheet growth or expansion of the company's asset base, while a decrease may indicate divestitures or debt repayment.
This represents the sum of all claims against a company's assets, combining obligations to external creditors and the re...
This is a standard accounting identity used across all industries to verify that assets equal the sum of liabilities and equity.
total_liabilities_and_equity| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.66B | $8.16B | $8.50B | $8.42B | $8.43B | $8.64B | $8.29B | $8.65B | $9.00B | $9.37B | $9.36B | $9.74B | $10.10B | $12.97B | $13.06B | $13.02B | $13.49B | $13.27B | $13.70B | $13.32B |
| QoQ Change | — | +6.5% | +4.2% | -1.0% | +0.1% | +2.5% | -4.0% | +4.3% | +4.1% | +4.1% | -0.1% | +4.0% | +3.7% | +28.4% | +0.6% | -0.3% | +3.6% | -1.6% | +3.2% | -2.7% |
| YoY Change | — | — | — | — | +10.0% | +5.9% | -2.5% | +2.7% | +6.9% | +8.5% | +12.9% | +12.5% | +12.2% | +38.4% | +39.4% | +33.7% | +33.6% | +2.3% | +4.9% | +2.3% |